PALATIN TECHNOLOGIES INC
Price data unavailable
Track PTN in your trading journalAbout PALATIN TECHNOLOGIES INC
PALATIN TECHNOLOGIES INC (PTN) is a publicly listed company on US equity markets.
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. The Company's business is in one operating segment: life science.
The company reports trailing twelve-month revenue of $8.83M and net loss of $1.43M.
Key metrics include a return on equity of -13.5%, a debt-to-equity ratio of 0.25.
Use FINOTAUR to track PTN's price action, review fundamentals, and stay current with company news — all in one research dashboard.
Fundamentals
| Revenue (TTM) | $8.83M |
| Net Income (TTM) | $-1.43M |
| EPS (TTM) | — |
| P/E Ratio | — |
| Return on Equity | -13.53% |
| Debt-to-Equity | 0.25 |
| Dividend per Share | — |
Recent News
- Benzinga·Dec 11
Why Are Palatin Technologies (PTN) Shares Spiking After-Hours?
- Benzinga·May 8
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025
- GlobeNewswire Inc.·Feb 9
Data la crescita esponenziale del settore del turismo in Arabia Saudita, dmg events annuncia il salone Hotel & Hospitality Expo
Want real-time analysis on PTN?
Track it free in your trading journal. Log trades, tag setups, and review your edge.